title: Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response.
abstract: OBJECTIVE
  To document the burden of early rheumatoid arthritis (RA) on health-related quality of life (HQL) and compare changes in HQL across 2 treatments.
  
  
  METHODS
  Analysis of HQL scores among patients enrolled in a multicenter, double-blind, randomized control trial of early RA treatment.
  
  
  METHODS
  A total of 424 patients with early RA were randomized to 1 of 2 treatment groups: etanercept or methotrexate. Patients were treated and followed for 52 weeks. Health-related quality of life was assessed before and throughout treatment using the Medical Outcomes Study Short Form 36 Health Survey (SF-36) and the Health Assessment Questionnaire (HAQ). The HQL burden of RA was established by comparing SF-36 scale scores to general US population norms. The impact of treatment on HQL was determined by comparing scores on both SF-36 and HAQ scales.
  
  
  RESULTS
  Before treatment, RA patients showed significant decrements in scores on all SF-36 scales and summary measures in comparison with age- and sex-matched general US population norms, multivariate analysis of variance (MANOVA) F(8,2815) = 204.6, P < .0001. After 52 weeks of treatment, 7 of 8 SF-36 scales and the physical summary measure remained significantly below the general US population norm, MANOVA F(8,2815) = 41.9, P < .0001. Patients randomized to etanercept showed significantly better HQL improvement earlier in treatment than patients randomized to methotrexate on the SF-36 physical summary, MANOVA F(10,4230) = 6.1, P< .0001, the SF-36 arthritis-specific health index, MANOVA F(10,4230) = 8.5, P < .0001, and the HAQ, MANOVA F(10,4230) = 14.7, P < .0001. At 52 weeks, there were no significant differences between treatment groups.
  
  
  CONCLUSIONS
  Rheumatoid arthritis places tremendous disease burden on patients' HQL. Successful treatment of early RA improved HQL. Etanercept showed a rapid HQL response.
authors.affiliation: QualityMetric, Inc, Lincoln, RI 02865, USA. mkosinski@qmetric.com
authors.forename: Mark
authors.initials: M
authors.lastname: Kosinski
authors.forename: Sara C
authors.initials: SC
authors.lastname: Kujawski
authors.forename: Richard
authors.initials: R
authors.lastname: Martin
authors.forename: Lee A
authors.initials: LA
authors.lastname: Wanke
authors.forename: Mary C
authors.initials: MC
authors.lastname: Buatti
authors.forename: John E
authors.initials: JE
authors.lastname: Ware
authors.forename: Eleanor M
authors.initials: EM
authors.lastname: Perfetto
mesh_terms: D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000523:psychology*; D017281:Cost of Illness; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use*; D008875:Middle Aged; D010147:Pain Measurement; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D018434:Sickness Impact Profile; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D014481:United States
chemical_list: D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept; D008727:Methotrexate